{"organizations": [], "uuid": "4ee65d6a0b29c8bd26e0c7de1261f38b6416853e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 1, "shares": 1, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-gsk-to-review-of-horlicks-consumer/brief-gsk-to-review-of-horlicks-consumer-nutrition-products-to-fund-novartis-deal-idUSFWN1R814E", "country": "US", "domain_rank": 408, "title": "BRIEF-GSK To Review Of Horlicks, Consumer Nutrition Products To Fund Novartis Deal", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T08:17:00.000+03:00", "replies_count": 0, "uuid": "4ee65d6a0b29c8bd26e0c7de1261f38b6416853e"}, "author": "", "url": "https://www.reuters.com/article/brief-gsk-to-review-of-horlicks-consumer/brief-gsk-to-review-of-horlicks-consumer-nutrition-products-to-fund-novartis-deal-idUSFWN1R814E", "ord_in_thread": 0, "title": "BRIEF-GSK To Review Of Horlicks, Consumer Nutrition Products To Fund Novartis Deal", "locations": [], "entities": {"persons": [], "locations": [{"name": "vemgal", "sentiment": "none"}, {"name": "nashik", "sentiment": "none"}, {"name": "karnataka", "sentiment": "none"}], "organizations": [{"name": "brief-gsk to review of horlicks", "sentiment": "negative"}, {"name": "glaxosmithkline plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}, {"name": "glaxosmithkline", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}, {"name": "novartis deal reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27, 2018 / 5:17 AM / Updated 24 minutes ago BRIEF-GSK To Review Of Horlicks, Consumer Nutrition Products To Fund Novartis Deal Reuters Staff 2 Min Read March 27 (Reuters) - Glaxosmithkline Plc: * GLAXOSMITHKLINE - TRANSACTION WITH NOVARTIS EXPECTED TO BE ACCRETIVE TO ADJUSTED EARNINGS IN 2018 AND THEREAFTER, AND TO STRENGTHEN CASH FLOW GENERATION * GSK ALSO TO INITIATE STRATEGIC REVIEW OF HORLICKS AND OTHER CONSUMER NUTRITION PRODUCTS TO SUPPORT TRANSACTION FUNDING. * ‍REVIEW WILL INCLUDE AN ASSESSMENT OF GROUP’S SHAREHOLDING IN INDIAN SUBSIDIARY, GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD​ * STRATEGIC REVIEW WILL INCLUDE AN ASSESSMENT OF GSK’S 72.5% SHAREHOLDING IN COMPANY * ‍EXPECTS OUTCOME OF STRATEGIC REVIEW TO BE CONCLUDED AROUND END OF 2018​ * GLAXOSMITHKLINE - CONSUMER HEALTHCARE BUSINESS TO CONTINUE TO INVEST IN GROWTH OPPORTUNITIES FOR OTC, ORAL HEALTH BRANDS, SUCH AS SENSODYNE AND ENO * GLAXOSMITHKLINE - ACTIVELY INVESTING IN PHARMACEUTICAL, VACCINES BUSINESSES, INCLUDING BUILDING NEW MANUFACTURING CAPACITY IN VEMGAL, KARNATAKA, NASHIK * GLAXOSMITHKLINE - BUYOUT TO BE STRUCTURED AS CANCELLATION OF NOVARTIS’ SHARES IN JV IN CONSIDERATION OF JOINT VENTURE PAYING BUYOUT PRICE TO NOVARTIS * GSK HAS ENTERED INTO A COMMITTED FACILITIES AGREEMENT TO SUPPORT FUNDING OF BUYOUT * AGREED TO PAY BREAK FEE OF $200 MILLION IN NOVARTIS DEAL * JOINT VENTURE WILL CONTINUE TO PAY DIVIDENDS TO GSK AND NOVARTIS IN ACCORDANCE WITH ITS ESTABLISHED PRACTICE UNTIL COMPLETION Further company coverage:", "external_links": [], "published": "2018-03-27T08:17:00.000+03:00", "crawled": "2018-03-27T08:49:03.014+03:00", "highlightTitle": ""}